Background: Artificial intelligence (AI) has contributed substantially in recent years to the resolution of different biomedical problems, including cancer. However, AI tools with significant and widespread impact in oncology remain scarce. The goal of this study is to present an AI-based solution tool for cancer patients data analysis that assists clinicians in identifying the clinical factors associated with poor prognosis, relapse and survival, and to develop a prognostic model that stratifies patients by risk. Materials and Methods: We used clinical data from 5275 patients diagnosed with non-small cell lung cancer, breast cancer, and non-Hodgkin lymphoma at Hospital Universitario Puerta de Hierro-Majadahonda. Accessible clinical parameters measured with a wearable device and quality of life questionnaires data were also collected. Results: Using an AI-tool, data from 5275 cancer patients were analyzed, integrating clinical data, questionnaires data, and data collected from wearable devices. Descriptive analyses were performed in order to explore the patients’ characteristics, survival probabilities were calculated, and a prognostic model identified low and high-risk profile patients. Conclusion: Overall, the reconstruction of the population’s risk profile for the cancer-specific predictive model was achieved and proved useful in clinical practice using artificial intelligence. It has potential application in clinical settings to improve risk stratification, early detection, and surveillance management of cancer patients.
PURPOSE: Stratifying patients with cancer according to risk of relapse can personalize their care. In this work, we provide an answer to the following research question: How to use machine learning to estimate probability of relapse in patients with early-stage non–small-cell lung cancer (NSCLC)? MATERIALS AND METHODS: For predicting relapse in 1,387 patients with early-stage (I-II) NSCLC from the Spanish Lung Cancer Group data (average age 65.7 years, female 24.8%, male 75.2%), we train tabular and graph machine learning models. We generate automatic explanations for the predictions of such models. For models trained on tabular data, we adopt SHapley Additive exPlanations local explanations to gauge how each patient feature contributes to the predicted outcome. We explain graph machine learning predictions with an example-based method that highlights influential past patients. RESULTS: Machine learning models trained on tabular data exhibit a 76% accuracy for the random forest model at predicting relapse evaluated with a 10-fold cross-validation (the model was trained 10 times with different independent sets of patients in test, train, and validation sets, and the reported metrics are averaged over these 10 test sets). Graph machine learning reaches 68% accuracy over a held-out test set of 200 patients, calibrated on a held-out set of 100 patients. CONCLUSION: Our results show that machine learning models trained on tabular and graph data can enable objective, personalized, and reproducible prediction of relapse and, therefore, disease outcome in patients with early-stage NSCLC. With further prospective and multisite validation, and additional radiological and molecular data, this prognostic model could potentially serve as a predictive decision support tool for deciding the use of adjuvant treatments in early-stage lung cancer.
Lung cancer exhibits unpredictable recurrence in low-stage tumors and variable responses to different therapeutic interventions. Predicting relapse in early-stage lung cancer can facilitate precision medicine and improve patient survivability. While existing machine learning models rely on clinical data, incorporating genomic information could enhance their efficiency. This study aims to impute and integrate specific types of genomic data with clinical data to improve the accuracy of machine learning models for predicting relapse in early-stage, non-small cell lung cancer patients. The study utilized a publicly available TCGA lung cancer cohort and imputed genetic pathway scores into the Spanish Lung Cancer Group (SLCG) data, specifically in 1348 early-stage patients. Initially, tumor recurrence was predicted without imputed pathway scores. Subsequently, the SLCG data were augmented with pathway scores imputed from TCGA. The integrative approach aimed to enhance relapse risk prediction performance. The integrative approach achieved improved relapse risk prediction with the following evaluation metrics: an area under the precision-recall curve (PR-AUC) score of 0.75, an area under the ROC (ROC-AUC) score of 0.80, an F1 score of 0.61, and a Precision of 0.80. The prediction explanation model SHAP (SHapley Additive exPlanations) was employed to explain the machine learning model's predictions. We conclude that our explainable predictive model is a promising tool for oncologists that addresses an unmet clinical need of post-treatment patient stratification based on the relapse risk while also improving the predictive power by incorporating proxy genomic data not available for specific patients.
Post-hoc explanation methods are used with the intent of providing insights about neural networks and are sometimes said to help engender trust in their outputs. However, popular explanations methods have been found to be fragile to minor perturbations of input features or model parameters. Relying on constraint relaxation techniques from non-convex optimization, we develop a method that upper-bounds the largest change an adversary can make to a gradient-based explanation via bounded manipulation of either the input features or model parameters. By propagating a compact input or parameter set as symbolic intervals through the forwards and backwards computations of the neural network we can formally certify the robustness of gradient-based explanations. Our bounds are differentiable, hence we can incorporate provable explanation robustness into neural network training. Empirically, our method surpasses the robustness provided by previous heuristic approaches. We find that our training method is the only method able to learn neural networks with certificates of explanation robustness across all six datasets tested.
This study presents a reusable, standardised framework for the preparation and retrospective analysis of large-scale electronic health record (EHR) data, developed through multidisciplinary collaboration between informatics, research design and specialist neurology expertise. The framework addresses persistent methodological barriers to EHR secondary analysis — including data quality assessment, terminology standardisation, and cohort construction — and is demonstrated through application to amyotrophic lateral sclerosis (ALS) using the IBM Explorys Real World Evidence database, encompassing approximately 54 million de-identified patient records. ALS was selected as the case study: its rarity necessitates large-scale data resources to achieve sufficient statistical power, while its phenotypic heterogeneity and well-documented diagnostic delays present substantive challenges for cohort construction and terminology standardisation. An ALS case cohort (n = 11,408) and an age- and gender-matched non-ALS control cohort (n = 34,206) were curated, and a retrospective epidemiological analysis was conducted across five annual windows prior to ALS diagnosis, examining comorbidities, signs and symptoms, and medication exposures. Framework validation was supported by replication of established pre-diagnostic ALS clinical patterns, including progressive neuromuscular and bulbar features and frontotemporal dementia co-occurrence. Beyond these validation signals, the analysis identified a consistent inverse association between metabolic syndrome-related comorbidities — including type 2 diabetes mellitus, obesity, and chronic kidney disease — and ALS risk across multiple pre-index windows. Convergent evidence from the medication analysis, particularly for oral glucose-lowering agents, reinforces this signal and identifies specific hypotheses for follow-up investigation. These findings highlight the potential of curated, standardised EHR data and multidisciplinary analytical frameworks for advancing rare disease research.